• Explore /
  • Poster
  • / Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa).

Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa).

Abstract Poster

Authors

null

Katherine L. Paweletz

Amgen Inc., South San Francisco, CA

Katherine L. Paweletz , Shyun Li , Julie M. Bailis , Gloria Juan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 155)

Abstract #

155

Poster Bd #

G13

Abstract Disclosures

Similar Posters

First Author: Julie Bailis

First Author: Mark Selby

First Author: Starlynn Clarke

First Author: Melissa Lynne Johnson